Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Development of a T-cell receptor mimic antibody against wild-type p53 for cancer immunotherapy
7d), suggesting that Gclc fl/fl Mb1-Cre + animals are unable to efficiently control LCMV Cl13 replication
Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response
Lu Y, Wang X, Gu Q, Wang J, Sui Y, Wu J, Feng J (2022) Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets
US$ 22.82
US$ 29.01
US$ 22.71
US$ 26.20
US$ 28.38
US$ 22.88
